An extension trial revealed that long-term anifrolumab treatment improved health status and health-related quality of life in ...

Lupus is a rare autoimmune disease characterized by chronic inflammation. It presents in four main forms: systemic lupus ...

This mysterious autoimmune disease presents with over 100 different symptoms, making diagnosis incredibly challenging for ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have been present for the past month.

Lupus Awareness Month shines a spotlight on a disease that affects millions worldwide yet remains widely misunderstood. Lupus ...

Since joining the Lupus Research Alliance (LRA) in 2015, Albert T. Roy has risen to the role of president and CEO. During ...

Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 ...

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Procalcitonin levels greater than 0.9 ng/mL may be a useful biomarker for identifying bacterial infections among febrile patients with JSLE.